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Abstract
Background: The new ruthenium(II)-arene complex, which bearing a carborane unit, ruthenium and ferrocenyl
functional groups, has a novel versatile synthetic chemistry and unique properties of the respective material at the
nanoscale level. The ruthenium(II)-arene complex shows significant cytotoxicity to cancer cells and tumor-inhibiting
properties. However, ruthenium(II)-arene complex of mechanism of anticancer activity are scarcely explored.
Therefore, it is necessary to explore ruthenium(II)-arene complex mechanism of anticancer activity for application in
this area.
Results: In this study, the ruthenium(II)-arene complex could significantly induce apoptosis in human lung cancer
HCC827 cell line. At the concentration range of 5 μM-100 μM, ruthenium(II)-arene complex had obvious cell
cytotoxicity effect on HCC827 cells with IC50 values ranging 19.6 ± 5.3 μM. Additionally, our observations
demonstrate that the ruthenium(II)-arene complex can readily induce apoptosis in HCC827 cells, as evidenced by
Annexin-V-FITC, nuclear fragmentation as well as DNA fragmentation. Treatment of HCC827 cells with the
ruthenium(II)-arene complex resulted in dose-dependent cell apoptosis as indicated by high cleaved Caspase-8,9
ratio. Besides ruthenium(II)-arene complex caused a rapid induction of cleaved Caspase-3 activity and stimulated
proteolytic cleavage of poly-(ADP-ribose) polymerase (PARP) in vitro and in vivo.
Conclusion: In this study, the ruthenium(II)-arene complex could significantly induce apoptosis in human lung
cancer HCC827 cell line. Treatment of HCC827 cells with the ruthenium(II)-arene complex resulted in dose-
dependent cell apoptosis as indicated by high cleaved Caspase-8,9 ratio. Besides ruthenium(II)-arene complex
caused a rapid induction of cleaved Caspase-3 activity and stimulated proteolytic cleavage of poly-(ADP-ribose)
polymerase (PARP) in vitro and in vivo. Our results suggest that ruthenium(II)-arene complex could be a candidate
for further evaluation as a chemotherapeutic agent for human cancers, especially lung cancer.
Background
Enormous interest has been focused on the research of
metallopharmaceuticals in order to find good alterna-
tives to platinum drugs because of their significant clini-
cal side effects and resistance that cause relapse of
cisplatin [1]. In recent years, ruthenium complexes have
attracted much interest because they exert their tumor-
inhibiting effects by a mode of action different from that
of Pt compounds [2]. Furthermore, they show a favor-
able toxicity profile in clinical trials: in the case of
the ruthenium-indazole complex KP1019 only very
moderate toxicities were observed in a dose range in
which proteins were on average loaded with one ruthe-
nium species, which should be sufficient for therapeutic
activity [3].
Recently, potential bio-active moieties, such as carbor-
ane and ferrocene (Fc), have been extensively involved
in new-type drug design because of their unique proper-
ties. Carboranes are carbon-containing polyhedral
boron-cluster compounds with globular geometry. Novel
carborane derivatives were synthesized to clarify its anti-
cancer activity [4]. A myriad of compounds containing
single- or multiple-carborane clusters were synthesized
and evaluated in both cellular and animal studies [5].
Carboranes are a class of carbon-containing polyhedral
boron-cluster compounds with remarkable thermal sta-
bility and exceptional hydrophobicity [6]. Carboranes
* Correspondence: xuewang@seu.edu.cn
1State Key Lab of Bioelectronics (Chien-Shiung Wu Lab), Department of
Biological Science and Medical Engineering Southeast University, Nanjing,
210096, PR China
Full list of author information is available at the end of the article
Zhang et al. Journal of Nanobiotechnology 2011, 9:6
http://www.jnanobiotechnology.com/content/9/1/6
© 2011 Zhang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.have been tried to apply to the field of boron neutron
capture therapy to incorporate large numbers of boron
atoms into tumor cells [7]. Meanwhile, Fc has been
incorporated in penicillin, chloroquine, tamoxifen, and
diphenols thus modifying relative activities due to its
small size, relative lipophilicity, ease of chemical modifi-
cation, and accessible one-electron-oxidation potential
[8,9]. Some unconjugated ferrocenyl derivatives and Fc-
containing bioconjugates, have shown promising bioac-
tivities like antineoplastic, antimalarial, or antibacterial
activities.
Recent studies illustrate that a structural change from
a Fc unit to a carboxyl group could lead to high selectiv-
ity toward cancer cells and facilitate the efficient inhibi-
tion of the proliferation of target cells, indicating that
the tuning of the overall properties of the ruthenium
(II)-arene complex by appropriate ligand tagging is criti-
cal to creating a selective anticancer agent [6]. In order
to improve the activity of ruthenium (II)-arene com-
plexes, which are of current interest as anticancer
agents, the ruthenium (II)-arene complexes were synthe-
sized by the reaction of ferrocenylacetylene in our work
(Figure 1A). The ruthenium(II) arene fragment coordi-
nation with a multidrug resistance (MDR) modulator
modified ligand (like anthracene) shows significant
improvement of the cytotoxicity and P-glycoprotein
inhibition behavior, demonstrating the promise of the
ruthenium arene fragment in biomedical realm [10].
Research in progress is concerned with the development
of advanced boron agents and neutron sources, other
than nuclear reactors, for the treatment of a variety of
cancer types using novel delivery methods [11].
However, ruthenium(II)-arene complex of mechan-
ism of anticancer activity are scarcely explored and
only a few dinuclear Ru complexes with tumor-inhibit-
ing properties are known [12]. In this study, the new
ruthenium(II)-arene complexes were observed to exhi-
bit relatively high in vitro and in vivo sensitivity to
HCC827 cells, resulting in dose-dependent cell apopto-
sis with a rapid induction of cleaved Caspase-3 activity
and stimulated proteolytic cleavage of poly-(ADP-
ribose) polymerase.
Methods
Cells, animals and chemicals
HCC827 (human lung cancer) cells purchased from the
Institute of Hematology of Tianjin, Chinese Academy of
Medical Sciences. The ruthenium (II)-arene complex
(Figure 1B) was synthesized as our previous report [6].
Fetal calf serum was from Hyclone, RPMI 1640 cell cul-
ture medium Penicillin, streptomycin, 3-(4,5-Dimethyl-
2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) (Gibco BRL, Grand Island, NY). Nude mice were
provided by the Animal Feeding Farm of National Insti-
tute for the Control of Pharmaceutical and Biological
Products (P.R. China). Annexin-V-FITC Apoptosis
Detection Kit (Calbiochem, USA), Apoptotic DNA lad-
der Isolation Kit (BioVision, USA), antibody (Cell Sig-
nalling Technologies, USA) was purchased from Jinsite
Biology Reagent Co.Ltd (Nanjing, China).
Transmission Electron Microscopy
The ruthenium (II)-arene complex was observed under
the transmission electron microscopy (Hitachi H-600-II)
with an acceleration voltage of 200 kV.
Cell growth inhibition study by MTT assay
Cells (2×10
3/well) were plated in 100 μLm e d i u m / w e l l
in 96-well plates. After overnight incubation, MTT
assays on HCC827 cells were treated with various con-
centrations of ruthenium (II)-arene complex. After treat-
ment for 48 hour, 20 μL MTT solution (5 mg/ml) was
added to each well. Four hours later, the supernatant
was removed and 100 μL DMSO was added per well.
Samples were then shaken for 15 min. Then the optical
density (OD) was read at a wavelength of 540 nm. All
experiments were performed in triplicate. Relative inhi-
bition of cell growth was expressed as follows: % = (1-
[OD]test/[OD]control)×100%.
Flow cytometry analysis
Cells were seeded in 12 well plates at 1×10
5 cells per
mL, 1 ml/well. After incubated for 72 h at 37°C, 5%
CO2, HCC827 cells treated with relative ruthenium (II)-
arene complex for 48 h.’Annexin-V-FITC Apoptosis
Detection Kit’ was used to determine apoptosis. Flow
Figure 1 Characterization of ruthenium (II)-arene complex.( A )
The transmission electron microscopy images of ruthenium (II)-
arene complex. (B) The image structural of ruthenium (II)-arene
complex.
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flow cytometer (BD Biosciences, USA).
AO staining for apoptotic cells
Cancer cells were seeded in 6-well plates (5×10
5/well)
and incubated on relevant ruthenium (II)-arene complex
for 72 h. To stain apoptotic cells, the cells were trypsi-
nized and centrifuged for 6 min before 50 μLo fA Od y e
mix (100 μg/mL acridine orange) was added to each well,
and cells were viewed under fluorescence microscope.
Intracellular ruthenium(II)-arene complex measurement
To measure intracellular ruthenium(II)-arene complex
accumulation, HCC827 cells in 60-mm plates were incu-
bated overnight in culture medium and then treated
with ruthenium(II)-arene complex for 2 hours. Cells
were harvested with a rubber scraper and centrifuged at
2,000 g for 10 min. The harvested cells were washed
three times in cold PBS. The cells were digested to mea-
sure iron levels. Cells were dried at 105°C and ground in
an agate mortar, and then digested in nitric acid. After
appropriate dilution with doubly distilled H2O (ddH2O),
the iron metal concentrations of the samples were deter-
mined by atomic absorption spectrophotometry using a
TAS-986 spectrophotometer with respect to appropriate
standard solutions in acidified ddH2O.
Apoptotic DNA fragmentation analysis
The HCC827 cells were treated with various concentra-
tions of the ruthenium (II)-arene complex for 72 h respec-
tively. The cells without treated were considered as
controls. Apoptotic DNA ladder of HCC827 cell was
extracted using Apoptotic DNA ladder Isolation Kit, and
then loaded onto 1% agarose gel. The DNA ladders stained
with ethidium bromide were visualized under UV light.
Apoptosis Western blotting analysis in vitro
HCC827 cells (1×10
5/well) were plated in 2 mL medium/
well in 6-well plates. After 72 hours treatment of relevant
ruthenium (II)-arene complex at the concentration (100
μM, 50 μM) treatment, HCC827 cells lysates were pre-
pared from treatment using modified RIPA lysis buffer.
The lysates subjected to SDS-PAGE/Western blot analysis.
The proteins were detected by enhanced chemilumines-
cence (ECL, GE Healthcare, NJ, USA). The following anti-
bodies were used: anti-Cleaved Caspase-3, anti- Cleaved
Caspase-9, anti- Cleaved Caspase-8, PARP, GAPDH levels
were measured to ensure equal loading of protein.
Experimental animals
HCC827 cells (4-5×10
6) were suspended in 200 μLo f
culture medium and subcutaneously inoculated into the
right flank of mice using a 1.0 mL syringe. Animals were
kept in the facility with free access to food and water.
Intravenous injection of reagents and tumor growth
inhibition study
T h en u d em i c ei n o c u l a t e dw i t hH C C 8 2 7c e l l sw e r e
divided into 3 groups with seven mice in each group: (1)
Control (n = 7); (2) 50 μmol/kg ruthenium (II)-arene
complex (n = 7); (3) 100 μmol/kg ruthenium (II)-arene
complex control (n = 7). When the tumor volume
became around 50 mm
3 after one week of inoculation,
treatment was injected for each group. Injection was
intravenously administered by tail vein at day 0, 2, 4, 6, 8,
10, 12, 14, 16 and 18. The tumor volume of nude mice
were measured and calculated at the 20th days after
treatment. The tumor volume calculation was performed
using the formula V = π/6×[(a+b)/2]
3, where a is the lar-
gest and b is the smallest diameter of the tumor.
Apoptosis Western blotting analysis in vivo
Briefly, the tumor tissues were removed from experi-
mental mice. The tumors photographed, and then used
for Western blot. The tumor lysis was subjected to Wes-
tern blot analysis. And the proteins were detected by
enhanced chemiluminescence (ECL, GE Healthcare, NJ,
USA). The following antibodies were used: anti-Cleaved
Caspase-3, anti- Cleaved Caspase-9, anti- Cleaved Cas-
pase-8, PARP, GAPDH levels were measured to ensure
equal loading of protein.
In situ apoptosis by TUNEL staining
Apoptotic cell death in deparaffinized tumor tissue sec-
tions was detected using terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labeling (TUNEL)
with the Klenow DNA fragmentation detection kit
(Roche, USA). Briefly, sections were permeabilized with
20 μg/mL protease K, and endogenous peroxidase was
inactivated by 3% H2O2 in methanol. Apoptosis was
detected by labeling the 3’-OH ends of the fragmented
DNA with biotin-dNTP using Klenow at 37ºC for 1.5
hours. The tumor slides were then incubated with strep-
tavidin horseradish peroxidase conjugate, followed by
incubation with 3,3’-diaminobenzidine and H2O2. Apop-
totic cells were identified by the dark brown nuclei
observed under light microscope.
Statistical analysis
Results were presented as Mean ± SD. A t-test was per-
formed in each group for each time point. A value of P
< 0.05 was considered statistically significant.
Results
Cytotoxicity of ruthenium(II)-arene complex on HCC827
cells
Initially, the synthesized ruthenium (II)-arene complex
was characterized by transmission electron microscopy.
The average size of the ruthenium (II)-arene complex
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ried out for the cells cytotoxicity study. The cells were
treated with different concentrations of ruthenium (II)-
arene complex (10 μM-100 μM) for 48 h. As shown in
Figure 2A, HCC827 cells viability was significantly
reduced after 48 h exposure to ruthenium (II)-arene
complex. Those cells growth inhibition were increased
in a dose-dependent manner. The IC 50 values of each
treatment were calculated, as shown in (Table 1).
Cell apoptosis rate induced by Ruthenium (II) Arene
Complex
Figure 2B shows that relevant ruthenium (II)-arene
complex induced a much higher cell apoptosis rate than
untreated control using Annexin-V-FITC apoptosis
detection method. We found that the percentage of
apoptotic cells was 8.9%, 25.2%, 43.4%, 65.2% for the
treatment with 0 μM, 10 μM, 50 μM, 100 μM ruthe-
nium (II)-arene complex, respectively (Figure 2C).
Ruthenium (II)-arene complex demonstrated a sus-
tained, dose-dependent anti-proliferative activity in
HCC827 cells. Using acridine orange staining for apop-
totic cells, apoptotic nuclei were identified by their dis-
tinctively marginated and fragmented appearance under
fluorescence microscope. The apoptotic nuclei of
HCC827 cells (Figure 3A, Apoptosis nuclei) at 72 hours
could be identified by their distinctively marginated and
fragmented appearance. For the control cells without
treatment, cells nuclei were normal as shown in (Figure
3A, control nuclei). In summary, each of the experimen-
tal methods performed demonstrated a substantial
increase in cell apoptosis following treatment of
HCC827 cells with relevant ruthenium(II)-arene
complex.
Apoptotic DNA fragmentation
To determine whether the cell cytotoxicity was due to
the apoptotic response, the DNA fragmentations were
examined by agarose gel electrophoresis. When
HCC827 cells were treated with 100 μM ruthenium
(II)-arene complex, the intensity of fragmented chro-
mosomal DNA bands was much higher than that
observed from cells treated with 50 μM ruthenium (II)-
arene complex (Figure 3B, lane 1, 2 respectively).
These results provide the evidence that the remarkable
enhancement of apoptosis was induced by the antican-
cer effect of relevant ruthenium (II)-arene complex on
HCC827 cells.
Intracellular ruthenium(II)-arene complex measurement
HCC827 cells uptake of ruthenium(II)-arene complex
was examined after 2 hours treatment. Figure 3C shows
the Fe levels in various treatments. When ruthenium
(II)-arene complex were injected into cells, the amount
of Fe in tested cells was significantly higher than those
in the control group. In accordance with this results, we
demonstrate that ruthenium (II)-arene complex was
intaken by cellular behavior with concentration-depen-
dent used in the experiment.
Figure 2 Measurement of cell apoptosis rate. (A) HCC827 cells MTT assay (1) 5 μM; (2) 10 μM; (3) 25 μM; (4) 50 μM; (5) 75 μM; (6) 100 μM.
The ruthenium (II)-arene complex treatment time was 48 hours. * P < 0.05, compared to the (1) treatment. (B) HCC827 cells detected by Flow
Cytometry using Annexin-V-FITC method. (a) control treatment; (b) 10 μM; (c) 50 μM; (d) 100 μM. The ruthenium (II)-arene complex treatment
time was 36 hours. (C) Quantitative analysis of apoptotic cells after various treatments shown in B. * P < 0.05, compared to the control
treatment.
Table 1 IC50 values of ruthenium (II)-arene complex
according to the MTT assays
IC50 values
Treatment type HCC827 cells
Ruthenium (II)-arene complex 19.6 ± 5.3 μM
The values are shown as mean ± SD, n =5 .
Note: IC50 values indicate the 50% growth inhibitory concentration values of
ruthenium (II)-arene complex.
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complex in HCC827 Cells
To further understand the molecular mechanisms
underlying the ruthenium(II)-arene complex mediated
apoptosis in HCC827 cells, we investigated apoptosis-
related protein expression in HCC827 cells. When
HCC827 cells were treated with 100 μM ruthenium
(II)-arene complex, the cleaved Caspase-8 (p43/p41) sig-
nals on Western blots were much stronger than those
for cells treated with 50 μM ruthenium(II)-arene com-
plex (Figure 4A). Similar results were obtained for
cleaved Caspase-9 and Caspase-3. PARP is a known
downstream target of active Caspase-3 and can be
cleaved during the induction of apoptosis. In HCC827
cells treated with 100 μM ruthenium (II)-arene com-
plex, the cleavage of PARP via the proteolytic degrada-
tion of most length PARP into the activated form was
detected along with Caspase-3 activation. Treatment of
cells with 50 μM ruthenium (II)-arene complex initiate
length PARP into the activated form was detected along
with Caspase-3 activation. These data suggest that
ruthenium (II) arene complex treatment induces cell
apoptosis by increasing activation of Caspase-8, 9 path-
ways in HCC827 cells.
Analysis of cell apoptosis in HCC827 xenograft tumors
The anticancer effect of ruthenium (II)-arene complex
on the apoptosis induction in the xenograft tumors
excised from HCC827 nude mice was evaluated. The
apoptotic rate in the HCC827 xenograft tumor on the
control group (Figure 5A, a) was about 9.1%. The apop-
totic rate in group 2 (HCC827 mice treated with 50
μmol/kg ruthenium (II)-arene complex) did increase to
about 46.7% significantly (Figure 5A, b). For group 3
(HCC827 mice treated with 100 μmol/kg ruthenium
(II)-arene complex), as compared to that of the control
group, the number of apoptotic cells were greatly
increased to about 65.9% (Figure 5A, c).
It is clear from Figure 5B that the tumor volume in
HCC827 nude mice the control group were the largest
(4000 mm
3,g r o u p1 ) .5 0μmol/kg ruthenium (II)-arene
complex greatly inhibited the tumor growth in HCC827
nude mice (1800 mm
3, group 2). In contrast to group 2,
100 μmol/kg ruthenium (II)-arene complex greatly
showed much more tumor growth inhibition in
HCC827 nude mice (500 mm
3, group 3). Those results
provide the fresh evidence that remarkable enhancement
Figure 3 Morphological images and genomic DNA apoptosis
and Cyclic voltammetry study. (A) Detection of apoptotic and
normal cells by Acridine Orange Staining. Apoptotic nuclei could be
identified by their distinctively marginated and fragmented
appearance. (B) The genomic DNA was isolated from the HCC827
cells that underwent various treatments. The DNA ladders were
visualized under UV light. Lane M: Molecular weight markers; Lane 1:
Cells treated with 100 μM ruthenium (II)-arene complex; Lane 2:
Cells treated with 50 μM ruthenium (II)-arene complex; Lane 3: DNA
isolated from HCC827 cells without any treatment. (C) Cyclic
voltammetry study of ruthenium (II)-arene complex residue outside
HCC827 cells after incubating. (a) ruthenium (II)-arene complex (10
μM); (b) ruthenium (II)-arene complex (10 μM) and cells for 1 h; (c)
ruthenium (II)-arene complex (10 μM) and cells for 2 h. Pulse
amplitude: 0.05 V; pulse width: 0.05 s; pulse period: 0.2 s.
Figure 4 Activation of the apoptosis signal pathway.( A )
Western blotting in vitro. Cell lysates were prepared from the cells
treated with 50 μM ruthenium (II)-arene complex, 100 μM
ruthenium (II)-arene complex. HCC827 cells without treatment were
used as a control. The following antibodies were used: anti-cleaved
Caspase-8, anti-cleaved Caspase-9, anti-cleaved Caspase-3, and anti-
PARP antibody. GAPDH was served as a loading control. (B) Western
blotting in vivo. Tumor lysates were prepared from the cells treated
with 50 μmol/kg ruthenium (II)-arene complex, 100 μmol/kg
ruthenium (II)-arene complex. HCC827 cells without treatment were
used as a control. The following antibodies were used: anti-cleaved
Caspase-8, anti-cleaved Caspase-9, anti-cleaved Caspase-3, and anti-
PARP antibody. GAPDH was served as a loading control.
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growth inhibition can be inhibited by anticancer effect
of ruthenium (II)-arene complex in vivo.
Antitumor signal pathway of ruthenium (II)-arene
complex in vivo
To further investigate whether the antitumor signal
pathway of ruthenium (II)-arene complex investigated in
a lung tumor model using HCC827 nude mice is consis-
tent with signaling apoptosis induction in vitro,t u m o r
samples from xenograft mice were subjected to Western
blot assays. Western blots using the tumor extracts
showed that 50 μmol/kg ruthenium (II)-arene complex
treatment increased relatively subsequent half of PARP
activation, whereas 100 μmol/kg Ruthenium (II) Arene
Complex treatment led to most activation of PARP
when compared with control (Figure 4B). PARP is a
known downstream target of cleaved Caspase-3.
Caspase-3 is a known downstream target of active
Caspase-8, 9. Similar results were obtained for cleaved
Caspase-8, 9, 3. When HCC827 cells were treated with
100 μmol/kg ruthenium (II)-arene Complex, the cleaved
signals on western blots were much stronger than those
for cells treated with 50 μmol/kg Ruthenium (II) Arene
Complex.
Discussion
The new ruthenium (II)-arene complex was about 1 nm,
ruthenium (II)-arene complex has nanocomposites and
biomaterials activity. So the complex may be used as
nanodrug, for cancer targeting, and intracellular labeling.
Although ruthenium (II)-arene complex is used as an
anti SMMC-7721 and HELF cancer drug [6], our group,
along with several others, reported that new ruthenium
(II)-arene complex could be used as an anti lung cancer
drug. Ruthenium (II)-arene complex could induce can-
cer cells apoptosis, the underlying molecular mechanism
to HCC827 cells was unclear. One possible mechanism
is that enhanced biomolecular recognition and transpor-
tation through the cell membrane because of the hydro-
phobic face provided by the arene ligands [13].
Consistent with previous observations, our current study
indicates that ruthenium (II)-arene complex treatment
activated Caspase-8, 9 pathways to induce apoptosis in
HCC827 cells.
Apoptosis is an important biological process in many
systems and can be triggered by a variety of stimuli
received by the cells [14]. Caspase-family represents the
key components of the apoptotic machinery within the
cells and consists of at least 14 different caspase pro-
teases in mammals [15]. There are two major pathways
of caspase activation with one of which is initiated by
TNF-family receptors that recruit several intracellular
proteins to form a ‘’death-inducing signaling complex’’
(DISC) upon external “death signal” stimulation, leading
to Caspase-8 activation and apoptosis; another major
apoptosis pathway targets mitochondria that release
Cytochrome c activates pro-Caspase-9; the initiator Cas-
pases, such as Caspase 8 and 9, activated via these two
pathways, can cleave and activate their downstream
effector Caspases, such as Caspase-3, thus propagating a
cascade of proteolysis that results in apoptosis [16].
Firstly, we analyzed the cells apoptosis morphology
from various angles regarding MTT assay, nuclei stain-
ing, DNA fragment assay. We demonstrated in this
study that ruthenium (II)-arene complex elicited an
anti-proliferative effect in dose-dependent manner in
HCC827 human lung cancer cells. The apparent IC50
values for relevant ruthenium (II)-arene complex are
estimated as 19.6 μM for HCC827 cells. In addition,
when cells were treated with ruthenium (II)-arene
Figure 5 Immunohistochemical staining of apoptotic cells in
HCC827 xenograft tumors. (A) TUNEL staining was performed on
tissue sections of HCC827 xenograft tumors treated as follows: (a)
group 1, control group; (b) group 2, 50 μmol/kg ruthenium (II)-
arene complex treatment; (c) group 3, 100 μmol/kg ruthenium (II)-
arene complex treatment. Arrows: TUNEL positive cells (indicate
apoptotic cells). Scale bars: 50 μm. (d) Quantitative analysis of
apoptotic cells after various treatments shown in (Figure 5. A a, b,
c). (B) Inhibition of tumor growth in HCC827 nude mice with
different treatments. (a) The different treatment effects on the
tumor growth inhibition in nude mice inoculated with HCC827
cells: group 1, no treatment, serve as a control group; group 2, 50
μmol/kg ruthenium (II)-arene complex treatment; group 3, 100
μmol/kg ruthenium (II)-arene complex. (b) Quantitative analysis of
tumor volume after various treatments shown in (Figure 5. B a).
Each data represents the mean ± standard deviation (n = 7).
*Indicates significant difference in comparison to the control group
(p < 0.05).
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features of apoptosis, such as chromosomal condensa-
tion and DNA fragment. With flow cytometry assay, we
analyze quantitative apoptotic cells after various treat-
ments. So the new ruthenium (II)-arene complex could
be used as inducing HCC827 cells apoptosis with rela-
tively low concentration. We also demonstrate that
ruthenium (II)-arene complex was intaken by cellular
behavior with concentration-dependent used the spec-
trophotometry experiment. So ruthenium (II)-arene
complex is effective chemical for anticancer due to the
unique properties of the respective material at the
nanoscale level.
In the current study, we found that ruthenium (II)-
arene complex treatments activated Caspase-8, 9 path-
ways to induce apoptosis in HCC827 cells. Cleaved Cas-
pase-8, Caspase-9 activated Caspase-3 that correlated
with the increased cleaved PARP expression after ruthe-
nium (II)-arene complex treatments (Figure 4A). And
then DNA fragmentation is induced during the cells
apoptosis by cleaved PARP expression. To further inves-
tigate whether the antitumor signal pathway of ruthe-
nium (II)-arene complex investigated in a lung tumor
model using HCC827 nude mice are consistent with sig-
naling apoptosis induction in vitro, tumor samples from
xenograft mice were subjected to Western blot assays
(Figure 4). The results provide the evidence that the
same antitumor signal pathway of ruthenium(II)-arene
complex induced in the HCC827 cells in vitro and in
vivo. Consequently, as shown in Figure 5, TUNEL
results demonstrate that tumor growth inhibition is
inhibited by apoptosis effect of ruthenium (II)-arene
complex in vivo. Therefore, the ruthenium (II)-arene
complex treatment might lead to the upregulation of
some TNF-family receptors activity and Cytochrome c
binds to the Caspase activator, which in turn may lead
to the degradation of the Caspase-8, 9 respectively. The
in vitro and in vivo assay results of the current study
further support this degradation of the Caspase protein,
suggesting the crucial role of the ruthenium (II)-arene
complex to induce cancer cell apoptosis.
Conclusion
In summary, our results show that the nanoscale level of
ruthenium (II)-arene complex induced significant apop-
tosis, and activation of Caspases in HCC827 cancer in
vitro and in vivo. The underlying apoptotic mechanism
was revealed to be crucially dependent on the activation
of Caspase-8, 9 that engaged at later stage at least.
These observations suggest that ruthenium (II)-arene
complex is a potential candidate for lung cancer che-
motherapy. Those results provide the evidence that
remarkable enhancement of apoptosis can be induced
and tumor growth can be inhibited by anticancer effect
of ruthenium (II)-arene complex in vivo.I ti se v i d e n t
that the better understanding of the apoptotic mechan-
ism and possible chemotherapeutic activity of ruthenium
(II)-arene complexs chemotherapeutic activity would
benefit the future clinical study.
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